Good morning :)
Place Order
Add to Watchlist

Astec Lifesciences Ltd

ASTEC

Astec Lifesciences Ltd

ASTEC
MaterialsFertilizers & Agro Chemicals
SmallcapWith a market cap of ₹2,095 cr, stock is ranked 1,119
Moderate RiskStock is 2.64x as volatile as Nifty
1,062.550.55% (-5.85)
1,062.550.55% (-5.85)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
MaterialsFertilizers & Agro Chemicals
SmallcapWith a market cap of ₹2,095 cr, stock is ranked 1,119
Moderate RiskStock is 2.64x as volatile as Nifty

How to use scorecard? Learn more

MaterialsFertilizers & Agro Chemicals
SmallcapWith a market cap of ₹2,095 cr, stock is ranked 1,119
Moderate RiskStock is 2.64x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-20.225.670.14%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
30.273.431.35%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Astec LifeSciences Limited is a holding company. The Company is a producer of agrochemicals and pharmaceutical intermediates.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 0.97%, vs industry avg of 10.43%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.34% to 0.22%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue240.19301.53395.02442.06534.54562.79687.04641.23463.82378.34
Raw Materialssubtract160.59179.66224.22295.05333.81344.60444.82460.83318.82444.08
Power & Fuel Costsubtract13.8415.7517.8723.8028.8025.2838.0445.6835.87
Employee Costsubtract15.8920.3821.7125.1029.9238.3550.3152.2661.74
Selling & Administrative Expensessubtract15.6213.6516.7415.4121.8317.1723.5525.7720.97
Operating & Other expensessubtract-1.3817.4433.43-4.9323.0717.92-34.22-32.6326.69
Depreciation/Amortizationsubtract10.4013.6814.6819.3523.1625.6634.3633.6536.2538.45
Interest & Other Itemssubtract12.8112.2410.6612.3812.594.759.0620.7125.2329.13
Taxes & Other Itemssubtract7.469.6220.8120.1713.8424.0231.269.39-14.81-29.72
EPS2.559.8117.8818.2924.2933.2245.8613.04-23.94-52.83
DPS0.001.501.501.501.501.501.501.501.500.00
Payout ratio0.000.150.080.080.060.050.030.110.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
MaterialsFertilizers & Agro Chemicals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Astec Lifesciences Ltd-44.645.670.14%
Fertilisers And Chemicals Travancore Ltd444.0347.180.10%
Coromandel International Ltd32.095.580.34%
UPL Ltd-38.351.410.16%

Price Comparison

Compare ASTEC with any stock or ETF
Compare ASTEC with any stock or ETF
ASTEC
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding66.75%4.00%0.51%0.53%28.21%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep1.95%1.33%1.28%1.25%1.03%0.53%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Astec Lifesciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Nippon India Small Cap Fund - Growth - Direct Plan

Growth
2.4306%0.08%-0.01%112/232 (-4)
TATA ASSET MANAGEMENT LTD#TATA MF-TATA RETIREMENT SAVINGS FUND-PROGRESSIVE-DIRECT PLAN-GROWTH

Growth
0.9019%0.90%-0.09%24/68 (-2)
ICICI Prudential Commodities Fund - Cumulative - Direct Plan

Growth
0.5828%0.50%-0.02%35/56 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ASTEC has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.14%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.40 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 21, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 21, 2023

Cash Dividend

Ex DateEx DateJul 19, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 19, 2022

Cash Dividend

Ex DateEx DateJul 22, 2021

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 22, 2021

Cash Dividend

Ex DateEx DateJul 16, 2020

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 16, 2020

Cash Dividend

Ex DateEx DateJul 18, 2019

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Jul 18, 2019

News & Opinions
Earnings
Astec Lifesciences reports consolidated net loss of Rs 38.56 crore in the September 2024 quarter

Net Loss of Astec Lifesciences reported to Rs 38.56 crore in the quarter ended September 2024 as against net loss of Rs 13.43 crore during the previous quarter ended September 2023. Sales declined 11.05% to Rs 98.55 crore in the quarter ended September 2024 as against Rs 110.79 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales98.55110.79 -11 OPM %-20.03-3.09 - PBDT-27.07-8.44 -221 PBT-38.54-17.60 -119 NP-38.56-13.43 -187 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Astec Lifesciences to hold board meeting

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 25 October 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Astec LifeSciences director resigns

Astec LifeSciences announced that Dr. Brahma Nand Vyas has tendered his resignation as an 'Independent Director' of the Company with effect from closure of business hours on 4 October 2024. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Astec Lifesciences announces resignation of Director cum CEO

Astec Lifesciences announced that Anurag Roy has tendered his resignation as the 'Whole Time Director & Chief Executive Officer' of the Company with effect from closure of business hours on 25 October 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Astec Lifesciences appoints director

Astec Lifesciences has appointed Dr. Ganapati Dadasaheb Yadav as a 'Non-Executive & Independent Director' of the Company with effect from 17 September 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live

Astec Lifesciences reports consolidated net loss of Rs 39.72 crore in the June 2024 quarter

4 months agoBusiness Standard
Earnings
Astec Lifesciences reports consolidated net loss of Rs 39.72 crore in the June 2024 quarter

Net Loss of Astec Lifesciences reported to Rs 39.72 crore in the quarter ended June 2024 as against net loss of Rs 8.19 crore during the previous quarter ended June 2023. Sales declined 51.44% to Rs 69.37 crore in the quarter ended June 2024 as against Rs 142.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales69.37142.85 -51 OPM %-66.672.19 - PBDT-52.37-1.62 -3133 PBT-61.64-11.01 -460 NP-39.72-8.19 -385 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Astec Lifesciences to discuss results

Astec Lifesciences will hold a meeting of the Board of Directors of the Company on 29 July 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Astec LifeSciences sinks 11% as Q4 earnings take a knock

1 year agoMoneycontrol

Astec LifeSciences tumbles 10% on loss in Q4; stock down 44% in six months

1 year agoBusiness Standard